Representative Emerson Levy (D-Central Oregon) introduced a legislative package in front of the House Committee on Health and Health Care designed to lower prescription drug costs and increase transparency in drug pricing. Building on her previous work, Levy introduced this bipartisan legislation to lower everyday costs for Oregonians and address health care affordability.
The package extends protections by adding members of the Public Employees’ Benefit Board and the Oregon Educators’ Benefit Board to the framework established by Levy’s 2024 Co-Pay Accumulator Ban, which requires insurers to accept third-party financial assistance to an enrollee’s annual deductible to pay for life-saving medicines.
The Pharmaceutical Manufacturer Assistance Transparency Bill, crafted by a bipartisan workgroup, mandates a study to collect data on prescription drug coupon usage—shedding light on how many Oregonians rely on these coupons and for which medications.
“Oregonians deserve to access their medications without unnecessary hassles and hurdles. These bills build on the foundation established by HB4113 and will ease the financial burden on Oregonians who rely on essential medications,” said Rep. Emerson Levy (D-Central Oregon).
Recent data underscores rising prescription costs and the growing need for clear, transparent practices in pharmaceutical pricing. By requiring targeted studies and expanding benefits board protections, this legislative package aims to deliver actionable insights and safeguard consumer interests amid evolving federal policies.
A recording of today’s hearing will be available on OLIS for those seeking further details.
